p53 gene therapy - MultiVir

Drug Profile

p53 gene therapy - MultiVir

Alternative Names: Ad-p53 - MultiVir; Adenoviral p53 - MultiVir

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator MultiVir
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver metastases

Most Recent Events

  • 01 Jun 2016 MultiVir initiates a phase I trial for Liver metastases (Combination therapy, Second-line therapy or greater) in USA (NCT02842125)
  • 14 Feb 2014 Phase-I clinical trials in Colorectal cancer (combination therapy, metastatic disease) in USA before February 2014 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top